Innovent Announces 2026 Interim Results and Business Updates

The provided article text contains only high-level promotional/introductory boilerplate about Innovent Biologics’ strategy for “growth and globalization,” without any disclosed financial results, guidance, or material operational metrics. No measurable catalysts (e.g., revenue/EPS, trial readouts, approvals, or capital actions) are included in the excerpt to assess impact on fundamentals or the market.